培门冬酶治疗结外NK/T细胞淋巴瘤的临床疗效

目的：分析结外 NK/ T 细胞淋巴瘤行培门冬酶与左旋门冬酰胺酶治疗的临床疗效。方法：以2009年6月至2014年12月病理诊断为结外 NK/ T 细胞淋巴瘤的患者为研究对象。将患者随机分为2组，培门冬酶组和左旋门冬酰胺酶组，两组均采用放疗以及以铂类为基础的两联方案化疗。在治疗结束后评价并对比患者的近期、远期疗效以及毒副反应。结果：共搜集结外 NK/ T 细胞淋巴瘤患者171例，其中培门冬酶组86例，左旋门冬酰胺酶组85例，近期疗效比较，P <0.05，差异有统计学意义，3个月、6个月、1年生存率比较，经Logrank 检验，P =0.000<0.05，培门冬酶组的3个月、6个月、1年生存率显著高于左旋门冬酰胺酶组；两组患者均出现了不同程度的血液学毒性及恶心、呕吐等反应，恶心、呕吐、过敏、高血糖等发生率比较，P <0.05，差异有统计学意义；白细胞、血小板下降、肝功能损害的发生率比较，P >0.05。结论：培门冬酶较左旋门冬酰胺酶可明显提高结外 NK/ T 细胞淋巴瘤的近期疗效。不良反应少，安全性高。

Comparative study of pegaspargase treatment of extranodal NK/T - cell lymphoma

Objective:To analyze extranodal NK/ T - cell lymphoma line pegaspargase clinical efficacy of L - as-paraginase. Methods:Extranodal NK/ T - cell lymphoma were patients selected,171 patients were randomly divided into two groups,pegaspargase group and L - asparaginase enzyme group. Two groups were treated with radiation and chemotherapy both platinum - based. Results:Total of 171 extranodal NK/ T - cell lymphoma patients,included pe-gaspargase group of 86 patients,L - asparaginase group 85 cases. Short - term effect,P < 0. 05,the difference was sta-tistically significant. 3 - month,6 - month,1 - year survival of the Logrank test,P = 0. 000 < 0. 05. 3 months pegaspar-gase group,6 - month,1 - year survival rate was significantly higher than that of L - door asparaginase. Patients in both groups experienced hematological toxicity and nausea,vomiting and other reactions,nausea,vomiting,allergies, high blood sugar and other incidences,P < 0. 05,the difference was statistically significant. White blood cells,platelets decreased,the incidence of liver dysfunction comparison,P > 0. 05,the difference was not statistically significant. Conclusion:Pegaspargase comparing L - asparaginase can significantly improve the short - term effect of extranodal NK/ T - cell lymphoma.